Colorectal Cancer Clinical Trials in Chicago, Illinois

12 studies are recruiting for colorectal cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

   This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in part…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   47 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06004245 on ClinicalTrials.gov

2. A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

   Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Chicago Medical Center /ID# 279365, Chicago, Illinois

   Locations

   73 in total

   Run by

   AbbVie

   See if you can join NCT07525206 on ClinicalTrials.gov

3. Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

   This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.

   Stage

   Not phased

   Ages

   65 to 82

   Site

   Northwestern Memorial Hospital, Chicago, Illinois

   Locations

   24 in total

   Run by

   Dartmouth-Hitchcock Medical Center

   See if you can join NCT05612347 on ClinicalTrials.gov

4. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

   Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug bei…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago Medical Center /ID# 274742, Chicago, Illinois

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT07023289 on ClinicalTrials.gov

5. A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with selected squamous solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago Medical Center - Oncology, Chicago, Illinois

   Locations

   41 in total

   Run by

   Alentis Therapeutics AG

   See if you can join NCT07169734 on ClinicalTrials.gov

6. CT-95 in Advanced Cancers Associated With Mesothelin Expression

   This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with M…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Context Investigational Site, Chicago, Illinois

   Locations

   9 in total

   Run by

   Context Therapeutics Inc.

   See if you can join NCT06756035 on ClinicalTrials.gov

7. Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

   An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally. CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants, obesity, alcohol, physical activity, red meat, and a Western diet). Design: a…

   Stage

   Not phased

   Ages

   18 to 49

   Site

   Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine University of Chicago Medicine, Chicago, Illinois

   Locations

   8 in total

   Run by

   San Raffaele University

   See if you can join NCT05732623 on ClinicalTrials.gov

8. FITting Non-invasive Tests in Lynch Syndrome Surveillance

   The purpose of this clinical study is to evaluate the accuracy of the fecal immunochemical test (FIT) in comparison to colonoscopy in patients with Lynch Syndrome (LS) who are undergoing colonoscopy surveillance.

   Stage

   Not phased

   Ages

   20 to 80

   Site

   The University of Chicago Medical Center, Chicago, Illinois

   Locations

   3 in total

   Run by

   University of Chicago

   See if you can join NCT06898996 on ClinicalTrials.gov

9. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

   This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   14 in total

   Run by

   858 Therapeutics, Inc.

   See if you can join NCT06395519 on ClinicalTrials.gov

10. A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

    The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

    Stage

    Phase 1

    Ages

    18 to 85

    Site

    University of Chicago, Chicago, Illinois

    Locations

    4 in total

    Run by

    Chimeric Therapeutics

    See if you can join NCT06055439 on ClinicalTrials.gov

11. Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

    This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

    Stage

    Not phased

    Ages

    60 and older

    Site

    John H Stroger Jr Hospital of Cook County, Chicago, Illinois

    Locations

    146 in total

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT03998202 on ClinicalTrials.gov

12. Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery

    A single arm, prospective, single center Phase1/2 Dietary intervention trial for subjects diagnosed with colorectal cancer and scheduled for tumor resection more than 21 days from informed consent. Subjects will be provided 21 days of standardized High-fiber/low-fat meals and complete a food diary …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Chicago, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT06349590 on ClinicalTrials.gov